Icon

Axsome Therapeutics Inc Stock Analysis and Price Target COMMON STOCK | Biotechnology | NSD

stockTargetAdvisor

Hold

Average User
Rating
stockTargetAdvisor

Buy

Average Analyst
Rating
stockTargetAdvisor

Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis

USD 62.88

-0.32 (-0.51)%

USD 2.78B

1.03M

USD 91.05(+44.80%)

USD 44.00 (-30.03%)

Icon

AXSM

Axsome Therapeutics Inc (USD)
COMMON STOCK | NSD
USD 62.88
-0.32 -0.506329
stockTargetAdvisor

Hold

Average User
Rating
stockTargetAdvisor

Buy

Average Analyst
Rating
stockTargetAdvisor

Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis

USD 2.78B

USD 44.00 (-30.03%)

USD 62.88

Axsome Therapeutics Inc Stock Forecast

Show ratings and price targets of :
USD 91.05
(+44.80%)

Based on the Axsome Therapeutics Inc stock forecasts from 14 analysts, the average analyst target price for Axsome Therapeutics Inc is USD 91.05 over the next 12 months. Axsome Therapeutics Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Axsome Therapeutics Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Axsome Therapeutics Inc’s stock price was USD 62.88. Axsome Therapeutics Inc’s stock price has changed by -0.77% over the past week, -0.91% over the past month and +88.83% over the last year.

No recent analyst target price found for Axsome Therapeutics Inc
No recent average analyst rating found for Axsome Therapeutics Inc

Company Overview

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate...Read More

https://www.axsome.com

22 Cortlandt Street, New York, NY, United States, 10007

383

December

USD

USA

Adjusted Closing Price

Loading...

Technical Indicators

Unadjusted Closing Price

Loading...

Assets

Top Holdings

Top Sectors

Top Regions

Share Volume

Loading...

Relative Performance

Symbol Capital Gain Dividend Return Total Return
Loading...

Stocks Similar To Axsome Therapeutics Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN
Regeneron Pharmaceuticals Inc +0.51 (+0.07%) USD81.74B 20.08 12.07

ETFs Containing AXSM

Symbol Name Weight Mer Price(Change) Market Cap
PTH
Invesco DWA Healthcare Mo.. 3.11 % 0.60 % -1.01 (-0.89%) USD0.18B

Frequently Asked Questions About AXSM Stock

Based on ratings from 14 analysts Axsome Therapeutics Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 9 buy, 1 sell and 5 hold ratings.

Unfortunately we do not have enough data on AXSM's stock to indicate if its a good dividend stock.

Based on targets from 14 analysts, the average taret price for AXSM is USD 91.05 over the next 12 months. The maximum analyst target price is USD 200 while the minimum anlayst target price is USD 52.

Unfortunately we do not have enough data on AXSM's stock to indicate if its overvalued.

The last closing price of AXSM's stock was USD 62.88.

The most recent market capitalization for AXSM is USD 2.78B.

Based on targets from 14 analysts, the average taret price for AXSM is projected at USD 91.05 over the next 12 months. This means that AXSM's stock price may go up by +44.80% over the next 12 months.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...